AI stock analysis · Drug Manufacturers - Specialty & Generic · Last analyzed Aug 16, 2026
Compass Score
4.0/5
Call
Buy
Price
$8.60
AI Target
$11.29 +31.3%
AI Analyst Summary
Xeris Biopharma is a specialty pharma company posting impressive 28.7% YoY revenue growth, driven by its commercial-stage portfolio including Gvoke (glucagon) and Recorlev (cortisol), with a clear trajectory toward profitability reflected in a 22.1x forward P/E. Analyst conviction is high — 6 of 7 analysts rate the stock a Buy with a mean price target implying over 31% upside from current levels. The primary risk is the company's continued losses and inconsistent earnings execution, which could delay the path to sustained profitability.
Catalysts
Continued Gvoke and Recorlev revenue ramp in upcoming quarterly results, with consensus expecting further top-line acceleration toward profitability milestones
Potential label expansions or new product launches within the specialty endocrinology portfolio that could meaningfully expand the addressable market
Possible positive inflection to EBITDA or operating profitability within the next 1–2 quarters, which could serve as a re-rating catalyst for the stock
Risks
Ongoing cash burn and loss-making status create dilution risk if the company needs to raise equity capital before reaching profitability
Commercial execution risk — Gvoke and Recorlev face competition from established players, and any slowdown in prescription growth could derail the revenue ramp
With only 7 analysts covering the stock, sentiment is concentrated; a single downgrade or missed quarter could disproportionately impact the share price
Fundamentals
PeN/A (loss-making) · 2.0/5
No trailing P/E available as the company is currently loss-making. Forward P/E of 22.1x is reasonable for a specialty pharma name approaching profitability, but the absence of current earnings warrants caution.
PegN/A · 3.0/5
PEG ratio is unavailable due to lack of trailing earnings. Defaulting to neutral score of 3; strong revenue growth of 28.7% YoY is a partial positive signal but insufficient to score higher without earnings visibility.
Analyst RatingStrong Buy consensus (1.4) · 5.0/5
7 analysts cover the stock with 6 Buys and 1 Hold. Consensus rating of 1.4 falls squarely in the Strong Buy range (1.0–1.5), reflecting high conviction across the analyst community.
Earnings TrendRevenue +28.7% YoY; EPS N/A · 3.0/5
The company is not yet profitable, so YoY earnings growth is unavailable. However, 28.7% revenue growth is a strong top-line signal. Scoring neutral as the path to earnings remains the key unknown.
Price Target Beat2 of 4 quarters beat · 2.0/5
Only 2 of the last 4 quarters saw EPS beats, indicating inconsistent execution relative to expectations. With limited history (4 quarters), this scores below average but not critically so.
ManagementMixed execution · 3.0/5
Strong analyst confidence and robust revenue growth suggest management is executing on the commercial strategy. However, the mixed EPS beat rate (2 of 4) and ongoing losses temper enthusiasm. Scoring neutral with a cautiously constructive lean.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.